

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 31st March 2017

- Share placement \$867k in January
- Cash balance as of 31st March, \$1,234k
- Share placement approved by shareholders in April for \$720k. Further \$300k received April.
- Version 2 clinical trial; superior results of quality of life improvements, sexual satisfaction scores and continence
- PeriCoach patent issued for Japan
- Production of version 3 PeriCoach system hardware

28th April 2017: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, has today released its Appendix 4C - Quarterly Cashflow report for period ending 31 March 2017.

During the quarter, the company received \$867k of placement funds. A further \$1,020k of placement funds were received in April.

The total cash outflow was \$888k, less than the \$955k projected. Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$23k, with extremely limited commercial activity occurring.

The Board and management appreciate the confidence of our major shareholders for supporting share placements (without discount), totalling \$1,887k. These funds are being deployed to continue the development of the PeriCoach® System with the rollout of v3 and advance negotiations with a licencing partner.

PeriCoach is a regulated medical device, built as a data collection and analysis system. The system provides opportunity for elevated insights into the management and motivation of the conservative treatment pathway for female pelvic floor disorders. This core capability is the driver for the pursuit of clinical evidence, in the forms of studies and surveys, as well as development of enhanced functionality of the PeriCoach system. Continued investment in real world data gathering tools to increase the sophistication of analysis of user behaviour and pelvic health information is the cornerstone of company strategy.

The controlled clinical trial achieved the objective to provide evidence to drive clinical acceptance of the PeriCoach. The highly significant scores achieved for quality of life and sexual function demonstrates the positive real world impact on improving women's lives.

Operationally the company remains tightly focused on release of the PeriCoach system v3 and its associated software. The enhanced functionality in v3 for users will simplify reporting of progress, incorporate symptom trackers, provide intuitive training guidance, and elevate the "in-app" experience. The system will also introduce training programs to address motivation and success factors. The capabilities of the v3 expands the market opportunity for PeriCoach and adds to the appeal for a potential licensing partner.

Analytica continues to secure patent protection in key geographies that have aging population, with the granting of patents in Japan.



“With tight focus on expenditure, the strong vote of confidence in the company by our major and long term shareholders, the positive results of the clinical trial and the introduction of v3 for real-world market evaluation, Analytica continues to execute its core business objective of securing a licence partner for PeriCoach.” said Analytica CEO Geoff Daly.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica’s lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.



Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Analytica Ltd

ABN

12 006 464 866

Quarter ended ("current quarter")

March 2017

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	23	61
1.2 Payments for		
(a) research and development	(396)	(962)
(b) product manufacturing and operating costs	(14)	(39)
(c) advertising and marketing	(29)	(250)
(d) leased assets		
(e) staff costs	(353)	(1,021)
(f) administration and corporate costs	(90)	(332)
1.3 Dividends received (see note 3)		
1.4 Interest received	4	11
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		1,155
1.8 Other (provide details if material)		3
1.9 Net cash from / (used in) operating activities	(855)	(1,374)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(1)	(3)
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities	(1)	(3)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	867	1,367
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options	(5)	(10)
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	862	1,357

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	1,228	1,254
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(855)	(1,374)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(1)	(3)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	862	1,357

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	1,234	1,234

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,234	1,234
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,234	1,234

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
110
0

--

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000

--

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	400	400
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Announced allotment capital raising approved EGM RIL of \$720k.

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	320
9.2 Product manufacturing and operating costs	85
9.3 Advertising and marketing	120
9.4 Leased assets	
9.5 Staff costs	320
9.6 Administration and corporate costs	150
9.7 Other (provide details if material)	
9.8 Total estimated cash outflows	955

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

